Jefferies Maintains Buy on Legend Biotech Corporation (LEGN) March 2026

Jefferies maintained a Buy on Legend Biotech Corporation (LEGN) on March 10, 2026. This LEGN analyst rating highlights Jefferies’ confidence in ongoing Carvykti sales momentum and keeps a $69 price target on the shares. The firm’s action is a maintenance, not an upgrade or downgrade, and follows recent commercial progress tied to the therapy. Investors should read this as continued analyst conviction rather than a new endorsement or reversal.